CClinicalTrials.gg
CompletedNCT02446782APTUpdated Jan 18, 2017

Efficacy and Safety of Prophylactic Use of an Antibiotic for Medical Thoracoscopy

A Phase 4 interventional study of Cefazolin and saline in Pleural Effusion, Pleurisy and Empyema, sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh. Completed at 1 site in India. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-01-18.

Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh · Phase 4, Interventional, and Prevention

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
12 Years to 80 Years
Sex
All
01

Study summary

This is a prospective study to assess the efficacy and safety of a single dose of cefazolin 2g IV for the prophylaxis of surgical site and pleural space infections in patients undergoing medical thoracoscopy.

Read the detailed description

This is a prospective randomized study to assess the efficacy and safety of a single dose of cefazolin 2g IV for the prophylaxis of surgical site and pleural space infections during medical thoracoscopy.

Consecutive patients who are planned to undergo a medical thoracoscopy (rigid or semirigid) will be enrolled in the study if they satisfy the inclusion and exclusion criteria. One hundred patients will be randomized in 1:1 ratio to receive either of the following: (a) A single dose of intravenous cefazolin 2 gms dissolved in 100 mL of normal saline administered over 10 minutes, between 15 and 30 minutes before the incision, OR (b) 100 mL normal saline administered intravenously over a period of 10 minutes between 15 and 30 minutes before the incision. Thoracoscopy will be performed in the bronchoscopy suite on a spontaneously breathing subject (fasting for 8 h) under conscious sedation (using midazolam, pentazocine, and tramadol) observing complete aseptic precautions.

02

Conditions studied

  • Pleural Effusion
  • Pleurisy
  • Empyema

Keywords

  • thoracoscopy
  • pleuroscopy
  • antibiotic prophylaxis
  • pleural effusion
03

Who can participate

Ages eligible
12 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age ≥12 years
  2. Medical thoracoscopy being performed for a pleural effusion for any of the three indications: diagnosis, pleurodesis, or adhesiolysis

Exclusion criteria

Exclusion Criteria:

  1. Age ≥80 years
  2. Pao2/FIO2\< 300;
  3. Hemodynamic instability
  4. Myocardial infarction or unstable angina in the last 6 wk
  5. Lack of pleural space due to adhesions
  6. Uncorrected coagulopathy
  7. Failure to provide informed consent
  8. Patients already taking any antibiotic due to any reason
04

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Cefazolin

    A single dose of intravenous cefazolin 2 gms will be administered over 10 minutes, dissolved in 100 mL of normal saline between 15 and 30 minutes before the incision. This will be preceded by an intradermal test dose to check for hypersensitivity to the drug. If hypersensitivity is present, the patient will be administered a single dose of intravenous Clindamycin 900 mg.

    Drug: Cefazolin

  • Placebo comparator
    saline

    100 mL normal saline will be administered intravenously over a period of 10 minutes between 15 and 30 minutes before the incision. An intradermal test dose with normal saline will be administered to this group.

    Other: saline

Interventions

  • DrugCefazolin

    Cefazolin 2 gm administered in 100 mL normal saline (after skin sensitivity testing) 15-30 minutes before the start of the procedure. Clindamycin 900 mg to be administered if sensitivity detected to cefazolin.

    Also known as: Clindamycin

  • Othersaline

    100 mL normal saline 15-30 minutes before the start of the procedure

05

What researchers measure

Primary outcomes

  1. Efficacy as assessed by occurrence of wound infection or pleural space infection

    (a) Occurrence of wound infection as indicated by development of a purulent discharge from the surgical site or (b) pleural space infection as indicated by development of purulence, fall in sugar levels or gram's stain or culture positivity in the pleural fluid drained by the chest tube on the side of the procedure.

    Time frame: 2 months

Secondary outcomes

  1. Safety as assessed by adverse effects

    Adverse effects arising as a result of the antibiotic administered

    Time frame: 7 days

06

Study locations

1 site
  • PGIMER
    Chandigarh, 160012, India
07

Registry details

Key details

Study ID
NCT02446782
Lead sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Responsible party
Sahajal Dhooria (Assistant Professor, Post Graduate Institute of Medical Education and Research, Chandigarh) — Principal investigator
First posted
May 18, 2015
Start date
Jan 2015
Primary completion
Apr 2016
Completion
Jun 2016
Last update
Jan 18, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion